Study design and setting
This is a randomized controlled trial, which will be conducted in the Department of Cardiology, the First Affiliated Hospital of Soochow University. A written informed consent will be obtained from each individual by the researcher after the individual has received a sufficient explanation and period of time in which to make a thoughtful decision. All the patients will be randomized 1:1 into the intervention group (n = 40) or the control group (n = 40). The intervention group is given 3-month positive events recording intervention on the basis of conventional nursing, while the control group received conventional nursing, and the two groups will be followed up for 6 months. The Cardiovascular Medicine Department of the First Affiliated Hospital of Soochow University is currently the largest cardiovascular disease diagnosis and treatment center in South Jiangsu Province, China. It has 180 beds, four cardiac catheterization rooms with advanced equipment, as well as a cardiac supersonic room and cardiac function room. Annually, an average of 5000 open-heart surgery candidates and 400 emergency operations are treated in the department. The protocol design is based on the Consolidated Standards of Reporting Trials (CONSORT) guidelines and Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist (see Additional file 3). Figure 1 presents a schematic flow diagram of the study.
Participants
Inclusion Criteria
Participants must meet the following criteria:
- those who are aged 8 years or older
- those who meet the diagnostic criteria of coronary heart disease in the ninth edition of Internal Medicine, including stable angina, unstable angina, myocardial infarction and acute coronary syndrome [30]
- those who after PCI
- those who agree to participate and provide written informed consent
- those who have been living in Suzhou for a long time or are not leaving Suzhou for half a year
- those who are clear-headed, normal-thinking and able to communicate with each other
Exclusion Criteria
Applicants who meet any of these conditions cannot participate in this study:
- those who have severe cognitive impairment, mental illness and non-cooperation
- those who have other serious diseases that affect survival, such as advanced cancer
- those who could not record for 4 consecutive weeks
- other reasons determined by the investigators that make participation in the clinical trial inappropriate
Withdrawal criteria
Participants who meet the criteria summarized below are withdrawn from the study. The subjects who are withdrawn after randomization will be followed up for outcomes. Reasons for withdrawal will be documented in follow-up records and data will be analyzed using the intention-to-treat (ITT) principle.
- all subjects have the right to withdraw for any reason
- those who could not complete the test as required, with serious adverse events and complications
- failed to have three consecutive telephone connections during the follow-up period
- at the end of the study
Randomization
Eligible participants who will provide written consent to take part in clinical trial will be randomly assigned to an intervention group or a control group with an allocation ratio of 1:1. Random sequencing will be generated by an independent professional statistician using the SPSS 25.0 software to generate 80 random numbers. The serial numbers assigned to each patient will be placed in an opaque sealed envelope and kept by the personnel not involved in the specific study. The participants will be randomly assigned to two groups, and each group will have 40 individuals.
Blinding
Member of the research team who enters the information is the only ones who know about the participants¢ allocation. The data collectors, random allocation program makers, data analysts and outcome evaluators are blinded to group allocation. And the participants are similarly blinded to their own group allocation. Participants are similarly blinded to their own group allocation and they will be told not to share their positive events records with others. Results from the outcome measures will not be revealed to the participants until after all recruitment, treatment, and assessments have been performed for all 80 participants.
Procedures
Recruitment
Participants will be recruited from The First Affiliated Hospital of Soochow University located in Suzhou, China. This institution will advertise the trial by posting recruitment posters on the hospital website or bulletin board.
Study schedule
The items to be measured at each visit are presented in Table1.
Baseline assessment
After the screening visit, if a participant fulfills the inclusion criteria and has signed the informed consent form, he will be assigned to the baseline assessment. The base-line assessment takes place at visit 1. Baseline assessment includes patients¢ basic information (such as age, gender, education, income, occupation, medical insurance, comorbidity, exercise, smoking habit, drinking habit, sleep pattern, etc.), body measurement (height, body weight, body mass index(BMI), blood pressure(BP), heart rate, etc.), clinical indicators (TG, TC, LDL, and blood glucose, etc.), questionnaires (Health Promotion Lifestyle Scale II (HPLP II), Self-rating Anxiety Scale (SAS), Positive Psychological Capital Questionnaire, General Well-Being Scale).
Table 1 Study schedule for the trial
Items
|
Screening
|
Post allocation
|
End of treatment
visiting 3 months
|
Visit 1
(day-7 to -2)
|
Visit 2
(day 0)
|
Visit 3
(week1)
|
Visit 4
(week 2)
|
Visit 5
(week 3)
|
Visit 6
(week4)
|
Visit 7
(week 8)
|
Visit8
(week12)
|
Visit9
(week24)
|
Informed consent
|
X
|
|
|
|
|
|
|
|
|
Inclusion/exclusion criteria
|
X
|
|
|
|
|
|
|
|
|
Randomization
|
|
X
|
|
|
|
|
|
|
|
Intervention
|
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
Basic informationa
|
X
|
|
|
|
|
|
|
|
|
Body measurementb
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
Vital signs
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
Medical historyc
|
X
|
|
|
|
|
|
|
|
|
General physical examination
|
X
|
|
|
|
|
|
|
X
|
X
|
Compliance monitoring
|
|
|
|
X
|
|
|
|
X
|
|
Healthy behaviours
|
X
|
|
|
|
|
|
|
X
|
X
|
Readmission rate
|
|
|
|
|
|
|
|
X
|
X
|
Anxiety
|
X
|
|
|
|
|
|
|
X
|
X
|
Psychological capital
|
X
|
|
|
|
|
|
|
X
|
X
|
Subjective well-being
|
X
|
|
|
|
|
|
|
X
|
X
|
Clinical indicatorsd
|
X
|
|
|
|
|
|
|
X
|
X
|
Adverse event monitoring
|
|
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
aAge, gender, job, medical insurance, exercise, smoking habit, drinking habit, sleep pattern, etc.
bHeight and weight, but only weight for visit 2 and follow-up
cIncluding general medical history and family history of CHD
dIncluding TG, TC, LDL, HDL, blood glucose etc.
Intervention
After randomization, the patients in the control group will receive conventional nursing, and the patients in the intervention group will record positive events for 3 months in addition to conventional nursing, that is, once a week for 12 weeks. Each patient in the intervention group will be assigned a notebook to record positive events and a health education manual. The specific implementation plan is as follows:
Intervention group
On the basis of the same conventional nursing as the control group, the following measures were given:
- Follow up: mainly by phone or Wechat, once a week in the first month after discharge, and once a month after that until 3 months. Each follow-up time is about 5-10 minutes. If the patient has any questions, the time can be extended as appropriate.
- Positive events recording guidance: the intervention plan was designed by our team based on the positive psychology intervention program by Seligman[25] and also based on a review of literature and expert consultation[31-33]. Related literature reported that the period of positive psychological intervention is generally more than 8 weeks[34]. Shang[29] improved the patients¢ negative emotions and promoted positive psychology through 8-week positive events recording intervention. Lan[22] conducted 10-week intervention on type 2 diabetes patients, and their depression and anxiety psychology was also effectively improved, and their self-care ability was improved too. So, the implementation time of positive events recording in this study is planned to be 3 months (see table 2).
- Recording log: each individual is given a recording log and asked to record the number and time of recording every day. The data will be used to assess intervention compliance.
Table 2 Outline of positive events recording for patients after PCI
Week
|
Specific measures
|
1
|
Review 3 events about your positive state this week and record them (for example, I finished my exercise today, and I took medicine under the doctor's advice today etc. It has nothing to do with the size of the matter)
|
2
|
Evaluate your strengths and apply them
|
3
|
Write a thank-you note
|
4
|
Complete 3 enjoyable and meaningful activities on your own
|
5
|
Review previous successful experiences
|
6
|
Accomplish three acts of kindness
|
7
|
Eliminate negativity (When there are negative emotions, record one thing that makes you happy)
|
8
|
Develop your own interests and hobbies
|
9
|
Set realistic goals and achieve them
|
10
|
Review the good events from your past life and summarize your life
|
11-12
|
For the next two weeks, repeat the above and practice or write it down
|
Control group
- Conventional nursing: on the first day after enrollment, researchers communicate with patients one-on-one, explain CHD related knowledge to patients, including risk factors, diet strategies, weight control, physical exercise, blood pressure and lipid management, etc. After the completion of the education, give the patients the corresponding education manual.
- Follow up by phone or Wechat: once per month for 3 months. Each call lasting about 5–10 min, receiving telephone or Wechat counseling from patients.
Outcome
The primary outcome indicators are healthy behaviours, readmission rate and anxiety level, the secondary outcome indicators are psychological capital, subjective well-being, clinical indicators (including TC, LDL, HDL, blood glucose, body mass index, etc.).
Primary outcome measure
- Healthy behaviours: The Health Promotion Lifestyle profile II (HPLP II) will be used to measure patient¢s healthy behaviours. The scale was revised by American nursing scientist Walker[35], which mainly includes 6 dimensions and 52 items. The total Cronbach's α coefficient of the scale is 0.94, and the Cronbach's α number of each dimension is 0.79-0.87. Each item is scored by grade 1-4, the higher the score, the better the healthful lifestyle. It will be checked at visit 1, 8 and 9.
- Readmission rate: In this study, readmission is defined as the readmission caused by cardiovascular problems, including hypertension, angina, arrhythmia, cardiac insufficiency, etc., excluding the cases of readmission due to cold, tumor and other factors. The readmission will be followed up by telephone for 3 months. The readmission information will be collected at visit 8 and 9.
- Anxiety: The self-rating anxiety scale (SAS) will be used to measure the anxiety of patients with CHD. The scale was compiled by Chinese professor Zung (1971), there are 20 items on the scale, each item is scored by grade 1-4, and items 5, 9, 13, 17 and 19 are scored in reverse. According to the results of Chinese norm model results[36], the cut-off value of the SAS standard score is 50, of which 50-59 is mild anxiety, 60-69 is moderate anxiety, and over 69 is severe anxiety. The scale has been widely used in China and its validity and reliability have been verified (Cronbach's α 0.82). The anxiety score will be measured at visit1, 8 and 9.
Secondary outcome measure
- Psychological capital: The positive psychological capital questionnaire (PPQ) is used to evaluate the patient¢s positive psychology. The questionnaire was revised by Professor Zhang et al.[37] of Nankai University on the positive psychological capital questionnaire compiled by Lutas et al. The questionnaire includes 26 items, Cronbach's α coefficient is 0.92, Cronbach's α coefficient of each dimension is 0.81, 0.76, 0.75, 0.78 respectively. The higher the score, the better the psychological capital. It will be measured at visit1, 8 and 9.
- Subjective well-being: The general well-being scale (GWB) is mainly used to evaluate the subjective well-being of patients. The scale was amended by Duan[38], a Chinese scholar, on the basis of Fazio. The scale includes 18 items, and the higher the score, the stronger the subjective well-being. The internal consistency coefficient of the scale is 0.91 for males and 0.95 for females. The internal consistency coefficient of retest is 0.85, and the correlation coefficient between subscale and total scale is 0.56-0.88. The subjective well-being score will be measured at visit1, 8 and 9.
- Clinical indicators: Clinical indicators will be followed up by researchers through Wechat or telephone to collect relevant clinical laboratory indicators of patients in 3 months, including BP, blood lipid, blood glucose, BMI, etc. The Clinical indicators will be collected at visit1, 8 and 9.
Safety outcome measure
The safety assessment will be performed for all subjects who have been randomized and recorded positive events more than once. The subjects¢ vital signs and general physical status will be examined at every visit. All participants will be required to report any adverse events (AE) that occur during the trial of visits 2,3, 4, 5, 6, 7, 8 and 9. All AEs that occur after the start of this trial should be recorded in the case report form, regardless of whether they are related to positive events recording or not. All AEs will be evaluated for causality.
Compliance monitoring and management
The researchers will collect the recording logs of the patients after 2 weeks of positive events recording for the purpose of calculating compliance. The compliance rate (%) = [continuous recorder as required/ total number of interventions] * 100%. Only when the compliance is≥70%, the research will continue, otherwise, find out the reasons and carry out scheme rectification.
Sample size calculation
Calculated according to the formula of sample size estimation based on the comparison of the mean of two independent samples [39]: σ is the standard deviation, d is the difference between the two population means, n1 and n2 are the required contents of the two samples respectively, Zα and Zβ are Z values corresponding to the type I error probability and the type II error probability respectively. At bilateral a = 0.05, power = 0.8, Z α / 2, ν = 1.96, Z β, ν = 0.842, σ = 12.68, δ = 10.39, the sample size for each group is 25 cases. Considering the 20% sample loss rate and other factors, the total number of samples is expected to be 80.
Data management and quality control of data
Both the case record form (CRF) and web-based electronic database will be used to manage individual participant data. To protect confidentiality, the files are stored in a secure and locked place and manner, the subject identification and private information will be deleted from all study documents. Quality control of the data will be handled at two different levels: the investigators will be required to ensure the accuracy of the data as the first level of control when they input the records in CRF. The second level will include data monitoring and validation that will be carried out by two full-time graduate students who will not be involved in the intervention or data collection. All the data will be double-inputted into the computer using Epidata3.0 software. After finishing the data entry and dealing with the query, the database will be locked under the orders of the principal investigator, and the SPSS software will be used for data analysis. No one is allowed to view the database without authorization, otherwise, they should notify the principal investigator.
Statistical analysis
The Kolmogorov–Smirnov test will be used to test the normal distribution of continuous variables. Continuous variables will be presented by mean ± standard deviation (SD) if they are normally distributed or by median with interquartile range if they are not normally distributed. For the comparison of measurement data between the two groups, t-test of two independent samples will be used for normal distribution data, and Mann Whitney U rank sum test will be used for non-normal distribution data. The comparison of count data between the two groups will be performed by c2 test or Fisher¢s exact test. An independent statistics expert will perform statistical analysis in a blind manner. SPSS for windows version 25.0 (SPSS Inc., Chicago, IL, USA) will be used for statistical analysis. The statistical level of significance will be set at P<0.05.